deltatrials
Suspended PHASE2 NCT01228656

Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate

CLINICAL EVALUATION OF EFFECTIVENESS OF ASSOCIATION MOMETASONE FUROATE 0.1% AND SALICYLIC ACID 5% COMPARED WITH 0.1% MOMETASONE FUROATE INSULATED TOPICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS IN PLATE

Sponsor: Azidus Brasil

Conditions Plaque Psoriasis
Interventions Mometasone furoate mometasone furoate + salicylic acid
Updated 6 times since 2017 Last updated: Nov 1, 2022 Started: Sep 30, 2006 Primary completion: Oct 31, 2010 Completion: Oct 31, 2011

This PHASE2 trial investigates Plaque Psoriasis and is currently suspended. Azidus Brasil leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Suspended PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE2

  3. Dec 2022 — Jul 2024 [monthly]

    Suspended PHASE2

  4. Jan 2021 — Dec 2022 [monthly]

    Suspended PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Suspended PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Suspended PHASE2

    First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Azidus Brasil
Data source: Azidus Brasil

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.